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The agmatine-containing poly(amidoamine) polymer AGMA1 was recently shown to inhibit the infectivity of several viruses,
including human papillomavirus 16 (HPV-16), that exploit cell surface heparan sulfate proteoglycans (HSPGs) as attachment
receptors. The aim of this work was to assess the antiviral activity of AGMA1 and its spectrum of activity against a panel of low-
risk and high-risk HPVs and to elucidate its mechanism of action. AGMA1 was found to be a potent inhibitor of mucosal HPV
types (i.e., types 16, 31, 45, and 6) in pseudovirus-based neutralization assays. The 50% inhibitory concentration was between
0.34g/ml and 0.73g/ml, and no evidence of cytotoxicity was observed. AGMA1 interacted with immobilized heparin and
with cellular heparan sulfates, exerting its antiviral action by preventing virus attachment to the cell surface. The findings from
this study indicate that AGMA1 is a leading candidate compound for further development as an active ingredient of a topical
microbicide against HPV and other sexually transmitted viral infections.
Human papillomaviruses (HPVs) are members of the Papillo-maviridae family of double-stranded DNA nonenveloped vi-
ruses (1). The 8-kb HPV genome is enclosed in a capsid shell
comprising major (L1) and minor (L2) structural proteins. Most
of the HPVs belonging to the Alphapapillomavirus genus are sex-
ually transmitted and infect the anogenital mucosa. For the great
majority of immunocompetent individuals, HPV infections are
transient, causing asymptomatic epithelial infections or benign
epithelial hyperplasia. Genital warts are themost common lesions,
caused mainly by HPV-6 and HPV-11. Small proportions of men
and women fail to control viral infections and develop HPV-re-
lated malignancies, including carcinoma of the cervix, vulva, va-
gina, penis, anus, or oropharynx. Several HPV types belonging to
HPV species 7 (HPV-18, HPV-39, HPV-45, HPV-59, and HPV-
68) or species 9 (HPV-16, HPV-31, HPV-33, HPV-35, HPV-52,
HPV-58, and HPV-67) can confer high oncogenic risk. HPV-16
and HPV-18 cause about 70% of all cases of invasive cervical can-
cer worldwide (followed by HPV-31, HPV-33, and HPV-45) (2).
It has been estimated that more than 528,000 new cases of
cervical cancer occur every year, and cervical cancer caused
266,000 deaths worldwide in 2012 (3, 4). Eighty-five percent of
cervical cancer cases occur in women living in low-socioeconomic
settings, primarily due to a lack of access to effective cervical can-
cer screening programs. No anti-HPV drugs are available to cure
HPV lesions; therefore, the current treatments are ablative and
directed at the abnormal cells associated with HPV, rather than at
the virus itself. The development of new ways to prevent genital
infections is essential in order to reduce the burden of HPV dis-
eases. Two prophylactic vaccines, Gardasil and Cervarix, are cur-
rently available. The first is designed to protect against oncogenic
HPV types 16 and 18 and low-risk HPV types 6 and 11 and there-
fore is preventive against both cancer and genital warts (5); the
latter is designed to protect against HPV types 16 and 18 only (5).
Although the protective activity of these vaccines is undeniable,
the vaccines also have a number of limitations, such as the lack of
protection against other oncogenic HPV types, the need for cold
chain distribution and storage, and low worldwide vaccine cover-
age, partly due to the very high costs of their administration. Ad-
ditional preventive tools for HPV infections are thus required,
particularly in low-resource settings where the burden of HPV
infections is greatest. In this context, topical antiviralmicrobicides
that could prevent the attachment of the full spectrum ofmucosal
HPVs to the epithelial cells lining the anogenital tract would be
extremely useful to complement the distribution of prophylactic
vaccines.
Primary attachment of papillomavirus particles to the cell sur-
face is mediated through the binding of HPV capsid proteins to
the cellular heparan sulfate proteoglycans (HSPGs) (6, 7), which
are polyanionic structures that are widely expressed on eukaryotic
cells and act as receptors for many other viruses (8–10). They
consist of a core protein with glycosaminoglycan (GAG) chains of
unbranched sulfated polysaccharides known as heparan sulfates,
which are structurally related to heparin. Consequently, heparin
and other polyanionic compounds have been reported to act as
HSPG antagonists, binding and sequestering HPV in the extracel-
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lular environment and thus hampering the cell surface attachment
of HPV and hence infection (references 11 and 12 and references
therein). The in vivo effectiveness of this anti-HPV strategy was
demonstrated recently using the polyanionic sugar carrageenan
(13, 14).
In addition to the virus-binding polyanionic compounds are
the polycationic compounds, which bind to and mask HSPGs,
preventing virus attachment. We showed recently that AGMA1, a
poly(amidoamine) (Fig. 1), displays antiviral activity against a
panel of viruses that utilize HSPGs as attachment receptors, in-
cluding HPV (11). The prevailing cationic nature of AGMA1 (15)
and its spectrum of antiviral activity suggest that it might prevent
virus infectivity by binding toHSPGs. The aimof the presentwork
was to investigate the antiviral activity of AGMA1 against several
low-risk and high-risk HPV types and to elucidate themechanism
of action of AGMA1. AGMA1 emerged as a broad-spectrum in-
hibitor of HPV infectivity that prevents HPV attachment by bind-
ing to and masking cell surface HSPGs.
MATERIALS AND METHODS
Materials. All solvents and reagents, unless otherwise indicated, were
analysis-grade commercial products and were used as received. 2,2-Bis(a-
crylamido)acetic acid (BAC) was prepared as reported in the literature,
and its purity (99.7%) was determined by nuclear magnetic resonance
(NMR) spectroscopy and titration (16). Phosphate-buffered saline (PBS)
(10 mM) was prepared using Sigma-Aldrich tablets, according to the
manufacturer’s instructions. D2O (99.9%) was purchased from Aldrich
and was used as received. Conventional heparin (13.6 kDa) was obtained
from Laboratori Derivati Organici S.p.A. (Milan, Italy). Heparinase II, a
glycosidase that digests the glycosaminoglycan (GAG) moiety of HSPGs
(17), was obtained from Sigma-Aldrich (St. Louis, MO). The heparan
sulfate-specificmonoclonal antibody 10E4 was kindly provided by G. Da-
vid (Leuven University, Leuven, Belgium).
Synthesis of AGMA1. AGMA1 (Fig. 1) was prepared as reported pre-
viously (18). Briefly, agmatine sulfate (2.000 g, 8.5 mmol) and lithium
hydroxide monohydrate (0.360 g, 8.5 mmol) were added to a solution of
2,2-bisacrylamidoacetic acid (1.689 g, 8.5 mmol) and lithium hydroxide
monohydrate (0.360 g, 8.5mmol) in distilled water (2.8ml). Thismixture
was maintained under a nitrogen atmosphere and stirred occasionally for
78 h. At the end of this period, it was diluted with water (100ml), acidified
with hydrochloric acid to pH 4 to 4.5, and then ultrafiltered through
membranes with a nominal molecular weight cutoff value of 5,000. The
fractions retained in each case were freeze-dried, and the product was
obtained as a white powder (yield, 1.9 g; AGMA1 number average molec-
ular weight, 7,800; weight average molecular weight, 10,100; polydisper-
sity, 1.29). Since AGMA1 is available in polydisperse preparations with
average molecular masses that are not unequivocally determinable, we
refer quantitatively to the compound in micrograms per milliliter (11),
with the exception of calculation of theKd (dissociation constant) value by
Scatchard analysis of the surface plasmon resonance (SPR) data.
Preparation of biotinylated AGMA1. Biotinylated AGMA1 (b-
AGMA1) was prepared in two steps, steps a and b, by reacting biotin
N-hydroxysuccinimide (NHS) ester (biotin-NHS) with modified AGMA1
carrying approximately 8% 2-aminoethyl-substituted units, which was
prepared by substituting in part agmatine with mono-tert-butoxycar-
bonyl (Boc)-ethylenediamine in the polymerization recipe and then
cleaving the protective group. In step a, 2,2-bisacrylamidoacetic acid
(5.0005 g), lithium hydroxide (1.0644 g), andmono-tert-Boc-ethylenedi-
amine (0.285 ml) were dissolved in distilled water (20 ml); the mixture
was stirred until clear and then allowed to stand in the dark at room
temperature (20°C) for 24 h. After that time, agmatine sulfate (5.500 g)
and lithium hydroxide (0.9936 g) were added with stirring, and the resul-
tant mixture was left standing for another 120 h, as described above, and
then diluted with water, acidified to pH 5 with hydrochloric acid, and
ultrafiltered through amembranewith a nominalmolecular weight cutoff
value of 3,000. The product was retrieved by lyophilization, dissolution in
2 M hydrochloric acid (50 ml), and stirring for 2 h at room temperature
under a slow stream of nitrogen, to favor elimination of the reaction
byproduct. The resultant aminated AGMA1 was then isolated as de-
scribed above (yield, 4.735 g).
In step b, aminated AGMA1 (0.500 g) was dissolved in water (25 ml),
the solution was brought to pH 9.0 with dilute sodium hydroxide, a solu-
tion of biotin-NHS (0.035 g) in dimethyl sulfoxide (DMSO) (2 ml) was
added dropwise, and themixture was stirred for 5 h at room temperature.
The reaction mixture was then acidified to pH 4.5, and the product was
isolated as in the previous cases, by dilution with distilled water, ultrafil-
tration, and lyophilization (yield, 330 mg; AGMA1 mean mass number,
8,400; mean molecular weight, 11,900; positive distribution, 1.42).
Size exclusion chromatography (SEC) traces were obtained with a
Knauer pump 1000 system equipped with a Knauer autosampler 3800,
TSKgel G4000 PW and G3000 PW columns (Tosoh) connected in series,
a light-scattering (LS) Viscotek 270 dual detector, aWaters 486 UV detec-
tor operating at 230 nm, and aWaters 2410 differential refractometer. The
mobile phase was 0.1 M Tris buffer (pH 8.00 0.05) with 0.2 M sodium
chloride. The flow rate was 1 ml/min, and the sample concentration was
1% (wt/wt).
HPVPsV production. Plasmids and 293TT cells used for pseudovirus
(PsV) productionwere kindly provided by John Schiller (National Cancer
Institute, Bethesda, MD) or were purchased from Addgene (Cambridge,
MA). Detailed protocols and plasmid maps for this study are available
online (http://home.ccr.cancer.gov/lco/pseudovirusproduction.htm).
HPV-16, HPV-31, HPV-45, HPV-6, and bovine papillomavirus 1
(BPV-1) PsVs were produced according to previously described methods
(19). Briefly, 293TT cells were transfected with plasmids expressing the
papillomavirusmajor andminor capsid proteins (L1 and L2, respectively)
together with a reporter plasmid expressing secreted alkaline phosphatase
(SEAP) or green fluorescent protein (GFP) (pYSEAP or pfwB, respec-
tively). HPV-16, HPV-6, and BPV-1 PsVs were produced using bicis-
tronic L1/L2 expression plasmids (p16sheLL, p6sheLL, and pSheLL, re-
spectively). Capsids were allowed to mature overnight in cell lysate; the
clarified supernatant was then loaded on top of an Optiprep density gra-
dient of 27 to 33 to 39% (Sigma-Aldrich, St. Louis, MO) at room temper-
ature for 3 h, to separate PsVs from cellular debris and empty capsids. The
material was centrifuged at 28,000 rpm for 18 h at room temperature in an
SW41.1 rotor (Beckman Coulter, Inc., Fullerton, CA) and then collected
by bottom puncture of the tubes.
Fractions were inspected for purity in 10% sodium dodecyl sulfate
(SDS)-Tris-glycine gels, titrated on 293TT cells to test for infectivity by
SEAP or GFP detection, and then pooled and frozen at 80°C until
needed. The L1 protein contents of PsV stocks were determined by com-
parisonwith bovine serumalbumin standards inCoomassie-stained SDS-
polyacrylamide gels.
FIG 1 Chemical structure of AGMA1.
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Cell culture.The human cervical carcinoma cell lines SiHa,HeLa, and
C33A were grown as monolayers in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco-BRL,Gaithersburg,MD) supplementedwith heat-inac-
tivated 10% fetal calf serum (FCS) (Gibco-BRL) and Glutamax-I (Invit-
rogen, Carlsbad, CA). The 293TT cell line, derived from human embry-
onic kidney cells transformed with the simian virus 40 (SV40) large T
antigen, was cultured in themediumdescribed above, supplementedwith
nonessential amino acids. The 293TT cell line allows high levels of protein
to be expressed from vectors containing the SV40 origin, due to overrep-
lication of the expression plasmid (20). Wild-type Chinese hamster ovary
(CHO)-K1 cells and GAG-deficient A745 CHO cells (21) were kindly
provided by J. D. Esko (University of California, La Jolla, CA) and grown
in Ham’s F-12 medium supplemented with 10% FCS.
GFP-based assays. Cells were seeded in 96-well plates at a density of
25,000 cells/well, in 100 l of DMEM supplemented with 10% FCS. The
next day, serial dilutions of AGMA1were added to preplated cells together
with dilutions of PsV stocks at a multiplicity of infection (MOI) of 0.05
(determined for each PsV genotype tested by calculation of the fraction of
cells positive for reporter protein expression in untreated cells, as reported
in reference 22). After 72 h of incubation at 37°C, fluorescent cells were
counted on an inverted Zeiss LSM510 fluorescence microscope.
SEAP-based PsV neutralization assays. The 293TT cells were seeded
in 96-well, tissue-culture-treated, flat-bottom plates at a density of 25,000
cells/well, in 100 l of DMEM without phenol red (Life Technologies,
Inc., Gaithersburg, MD) and with 10% heat-inactivated FCS, 1% gluta-
mate, 1% nonessential amino acids, 1% antibiotic-antimycotic solution
(Zell Shield; Minerva Biolabs GmbH, Berlin, Germany), and 10 mM
HEPES (neutralization buffer). The following day, to generate dose-re-
sponse curves, diluted PsV stocks (80 l/well) were combined with 20 l
of serially diluted compound. The 100-l PsV-compound mixture was
transferred to the cell monolayers and incubated for 72 h at 37°C at an
MOI of 0.05 (calculated by comparingCoomassie-stained SDS-polyacryl-
amide gels for SEAP and GFP PsVs, after having verified a linear correla-
tion between PsV amounts and relative light unit [RLU] values). Follow-
ing incubation, 50-l aliquots of supernatant were collected, and the
SEAP contents in the clarified supernatant were determined by using a
Great Escape SEAP chemiluminescence kit 2.0 (BD Clontech, Mountain
View, CA), as directed by the manufacturer. Thirty minutes after the
addition of the substrate, samples were assessed using a Wallac 1420 Vic-
tor luminometer (PerkinElmer Life and Analytical Sciences, Inc., Welles-
ley, MA). The 50% inhibitory concentration (IC50) values and the 95%
confidence intervals (CIs) were determined using the Prism program
(GraphPad Software, San Diego, CA).
Virus inactivation assay.Diluted stocks of PsVs containing GFP (105
focus-forming units) and the test compounds at concentrations of 3.6
g/ml were added to minimal essential medium (MEM) and mixed in a
total volume of 100l. The virus-compoundmixtures were incubated for
2 h at 37°C or 4°C and then serially diluted to a noninhibitory concentra-
tion of test compound, and the residual viral infectivity was determined.
Attachment assay. Serial dilutions of AGMA1weremixed with HPV-
16–SEAP PsV (MOI, 0.05) and added to cooled 293TT cells in 96-well
plates, and the cells were incubated for 2 h at 4°C to ensure PsV attach-
ment but not entry. After two gentle washes, the cells were shifted to 37°C,
and SEAP activity wasmeasured in the cell culture supernatants 72 h after
PsV inoculation.
Preattachment assays. Monolayers of 293TT cells in 96-well plates
were incubated with serial dilutions of AGMA1 for 2 h at 4°C. After re-
moval of the compound and gentle washing, HPV-16–SEAP PsV (MOI,
0.05) was added to the cells for 2 h at 4°C. After two gentle washes, the cells
were shifted to 37°C, and SEAP activity was measured in the cell culture
supernatants 72 h after PsV inoculation. Alternatively, HeLa cells were
incubated with a fixed dose of AGMA1 for 1 h at 37°C. After removal of
the compound and gentle washing, cells were overlaid with medium for
different times (23, 5, 3, or 1 h) and then infected with HPV-16–GFP PsV
(1 ng/ml L1). Fluorescencewas evaluated in the cell cultures 72 h after PsV
inoculation.
Postattachment assay. HeLa cell monolayers in 96-well plates were
incubated with HPV-16–GFP PsV (MOI, 0.05) for 2 h at 37°C, followed
by two gentle washes to remove unbound virus. Serial dilutions of
AGMA1 were added to cultures after washout of the inocula or after 2 or
4 h. Fluorescence was evaluated in the cell cultures 72 h after PsV inocu-
lation.
Entry assay.HeLa cell monolayers in 96-well plates were incubated
with HPV-16–GFP PsV (MOI, 0.05) for 2 h at 4°C, followed by two
gentle washes to remove unbound virus. Serial dilutions of AGMA1
were then added to the cultures, which were shifted to 37°C and incu-
bated for 5 h to allow virus entry. After this incubation, cells were
washed with medium or PBS at pH 10.5 (23) to remove virus that had
not entered the cells, followed by two washes with normal medium to
restore the physiological pH. Fluorescence was evaluated in the cells 72
h after PsV inoculation.
Postentry assay. HeLa cell monolayers in 96-well plates were incu-
bated with HPV-16–GFP PsV (MOI, 0.05) for 2 h at 4°C, followed by
two gentle washes to remove unbound virus. The cells were then
shifted to 37°C for 5 h to allow virus entry. After this incubation, cells
were washed with PBS at pH 10.5 (23) to remove virus that had not
entered the cells, followed by two washes with normal medium to
restore the physiological pH. Serial dilutions of AGMA1 were then
added to the cells. Fluorescence was evaluated in the cells 72 h after PsV
inoculation.
Cell viability assay. Cells were seeded at a density of 25,000 cells/well
in 96-well plates; the next day, they were treated with serially diluted
peptide compounds to generate dose-response curves. After 72 h of incu-
bation, cell viability was determined using the CellTiter 96 proliferation
assay kit (Promega, Madison, WI), according to the manufacturer’s in-
structions. Absorbance values were measured at 490 nm using a micro-
plate reader (model 680; Bio-Rad), and 50% cytotoxic concentration
(CC50) values and 95% confidence intervals (CIs) were determined using
Prism software (GraphPad Software, San Diego, CA).
Electron microscopy. An aliquot of diluted HPV-PsV preparation
was allowed to adsorb for about 3 min on carbon- and Formvar-coated
grids, and then the grids were rinsed several times with water. Grids were
negatively stained with 0.5% uranyl acetate, and excess fluid was removed
with filter paper. Observations and photographs were made using a CM
10 electron microscope (Philips, Eindhoven, The Netherlands).
Attachment and pretreatment followed by Western blotting. HeLa
cells were seeded at a density of 300,000 cells/well in 6-well plates; the next
day they were treated with a fixed dose of AGMA1 or heparin (i.e., 100
g/ml) 2 h before or during the 4-h infection period (MOI, 0.5), at 4°C.
Following incubation, cells were washed with cold medium to ensure the
removal of unbound virus; the cells were then collected and lysed. The
lysate proteins were separated by SDS-PAGE and transferred to a polyvi-
nylidene difluoride (PVDF) membrane. L1 was detected using a mouse
monoclonal antibody (Ab30908; Abcam, Cambridge, United Kingdom)
at a 1:2,000 dilution, followed by horseradish peroxidase (HRP)-conju-
gated anti-mouse IgG (Santa Cruz Biotechnology, Inc.). Actin was de-
tected using a mouse monoclonal antibody (anti-actin MAB1501R; Mil-
lipore), followed by HRP-conjugated anti-mouse IgG (Santa Cruz
Biotechnology, Inc.).
AGMA1/cell-associated HSPG binding assays. Monolayers of
CHO-K1 cells, GAG-deficient A745 CHO-K1 cells, or HeLa cells in 96-
well plates were incubated for 2 h at 4°C in phosphate-buffered saline
(PBS) containing 0.1 mg/ml CaCl2, 0.1 mg/ml MgCl2, and 0.1% gelatin,
with subsaturating concentrations of biotinylated AGMA1 (b-AGMA1)
(0.01 g/ml or 0.1 g/ml), in the absence or presence of heparin (10
g/ml). At the end of the incubation, cells were washed with PBS, and the
amounts of cell-associated b-AGMA1were determinedwithHRP-labeled
streptavidin (1:5,000) and the chromogenic substrate ABTS [2,2=-azino-
bis(3-ethylbenzthiazolinesulfonic acid)] (Kierkegaard & Perry Laborato-
Cagno et al.
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ries, Gaithersburg, MD). In some experiments, cell monolayers were
washed with PBS alone or PBS containing 2 M NaCl, a treatment known
to remove cationic polypeptides from cell surface HSPGs (24). Alterna-
tively, cells were incubated for 1 h at 37°C with culture medium alone or
medium containing heparinase II (15 mU/ml), before the binding assay.
In previous experiments, these experimental conditions have been dem-
onstrated to inhibit almost completely HSPG-dependent binding and bi-
ological activities of different heparin-binding proteins in various cell
types (25, 26), including epithelial cells (27, 28). To evaluate the efficiency
of the heparinase treatment, monolayers of HeLa cells on glass coverslips
were incubated for 1 h at 37°C with culture medium alone or medium
containing heparinase II (15 mU/ml), fixed with 3% paraformaldehyde
and 2% sucrose in PBS, and saturated with PBS containing 3% bovine
serum albumin. Then cells were incubated with the heparan sulfate-spe-
cificmonoclonal antibody 10E4 (1:200), followed by a 45-min incubation
with fluorescein isothiocyanate (FITC)-conjugated goat IgM (1:200) di-
rected against mouse IgM. Cells were photographed using an Axioplan 2
microscope equipped for epifluorescence (Carl Zeiss, Gottingen, Ger-
many) (original magnification,630).
SPRassay. Surface plasmon resonance (SPR)measurementswere per-
formed with a BIAcore X instrument (GE Healthcare, Milwaukee, WI),
using a research-grade CM3 sensor chip. The reagents 1-ethyl-3-(3-di-
aminopropyl)carbodiimide hydrochloride (EDC) andN-hydroxysuccin-
imide (NHS) were purchased from GEHealthcare and were used accord-
ing to recommended protocols.
To study the interaction of AGMA1 with heparin, the latter was im-
mobilized on a BIAcore sensor chip as described previously (24). Briefly,
a CM3 sensor chip (GE Healthcare) previously activated with 50 l of a
mixture containing 0.4 M EDC and 0.1 M NHS was coated with strepta-
vidin. Heparin was biotinylated at its reducing end and immobilized onto
the streptavidin-coated sensor chip. These experimental conditions al-
lowed the immobilization of 80 resonance units (RU), equal to 5.8 fmol/
mm2 of heparin. A sensor chip coatedwith streptavidin alonewas used for
evaluation of the nonspecific binding of AGMA1 to the sensor chip and
for blank subtraction. The compound was resuspended in 10 mM
HBS-EP buffer (HEPES buffer [pH 7.4] containing 150 mMNaCl, 3 mM
EDTA, and 0.005% surfactant P20) and injected over the heparin or
streptavidin surfaces for 4 min (to allow association with immobilized
heparin), and then the sensor chip was washed until dissociation was
observed. After every run, the sensor chip was regenerated by injection of
2 M NaCl. The Kd (dissociation constant) was calculated by using the
koff/kon ratio or by Scatchard analysis of the SPR RU values at equilibrium
(directly proportional to the moles of bound ligand) as a function of the
ligand concentration in solution.
RESULTS
Characterization of purified HPV-16 PsV. HPV-16 was chosen
as amodel virus because it is themost frequent genotype identified
in cervical carcinomas (29). First, we evaluated the quality of the
HPV-16–SEAP PsV preparations by SDS-PAGE and electron mi-
croscopic analysis. As shown in Fig. 2A, amajor bandmigrating at
55 kDa was detected by Coomassie brilliant blue staining (Fig. 2A,
lane 1) and was confirmed to be the L1 major capsid protein by
Western blotting with anti-L1 antibody (Fig. 2A, lane 2). No L1-
reactive proteolytic degradation productswere observed atmolec-
ular masses below 55 kDa. Figure 2B shows an electron micro-
graph of the same PsV stock. The PsV particles exhibited an
average diameter of 50 to 60 nm, similar to that of an authentic
HPV capsid, and appeared as well-defined individual particles
with no aggregation. When observed at a higher magnification,
the particles appeared to be well-assembled icosahedral capsids
(Fig. 2B, inset). Similar results were obtained with the other PsV
types used in this study (data not shown).
Inhibition ofHPV-16PsV infectivity in different cell lines by
AGMA1. The ability of AGMA1 to block HPV-16 PsV infection
was tested with several cell lines. 293TT cells are preferred for
PsV inhibition assays based on SEAP expression, because high
levels of the SV40 large T antigen in these cells allow overrep-
lication of the SEAP reporter plasmid (20). Moreover, the anal-
ysis was extended to cell lines derived from the uterine cervix
(i.e., SiHa, HeLa, and C33A), the major anatomical target for
high-risk HPV infections. Unlike 293TT cells, these cell lines
do not express the SV40 large T antigen, resulting in very low
levels of SEAP protein expression. Therefore, we employed
GFP as a reporter gene, because it allows reliable analyses of cell
types in which the reporter plasmid is not overreplicated. GFP-
expressing PsVs were also tested in 293TT cells and the IC50s
were compared to those obtained with SEAP-expressing PsVs.
As reported in Table 1, AGMA1 inhibited the infectivity of
HPV-16 PsV in all cell lines tested, with IC50s between 0.38
g/ml and 0.53 g/ml. Of note, the results showed that the
IC50s obtained from cells infected with GFP-expressing versus
SEAP-expressing PsVs were comparable. Cell viability assays
performed under culture conditions identical to those used for
antiviral assays (i.e., cell density and time of incubation with
the compound) demonstrated that AGMA1 did not affect cell
viability at any concentration tested (i.e., up to 300 g/ml).
Inhibitory activity of AGMA1 is not papillomavirus type re-
stricted. To assess whether the inhibitory activity of AGMA1 was
papillomavirus type specific, the assays were repeated in 293TT
cells using two additional high-risk HPV types (i.e., HPV-31 and
HPV-45), one low-risk type (HPV-6), and bovine papillomavirus
1 (BPV-1). The results shown in Table 2 demonstrate that
AGMA1 inhibited infectionwith all of the papillomaviruses tested
FIG 2 Characterization of purified HPV-16–SEAP PsV. (A) An aliquot of
purified PsV preparationwas analyzed by SDS-PAGEwithCoomassie brilliant
blue staining (lane 1) or immunoblotted with an anti-L1 antibody (lane 2).
MW, molecular weight (in thousands). (B) Electron micrograph of a purified
PsV preparation (bar, 100 nm). Inset, pseudovirus at2 magnification.
TABLE 1 AGMA1 antiviral activity against HPV-16 in different cell
lines
Cell line
IC50 (95% CI)
(g/ml)a CC50 (g/ml) SI
293TT, SEAP 0.53 (0.51–0.54) 300 566
293TT, GFP 0.38 (0.30–0.48) 300 785
HeLa 0.38 (0.28–0.52) 300 777
SiHa 0.38 (0.34–0.42) 300 779
C33A 0.49 (0.38–0.63) 300 606
a Values are means and CIs for three separate determinations. IC50, 50% inhibitory
concentration; CI, confidence interval; CC50, 50% cytotoxic concentration; SI,
selectivity index.
Anti-HPV Activity of AGMA1
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with similar potencies, indicating that the inhibitory activity of
AGMA1 is not type restricted.
AGMA1 does not inactivate HPV PsV particles. To assess
whether the inhibitory activity was a consequence of direct inac-
tivation of PsV particles by AGMA1, we performed a viral inacti-
vation assay. As shown in Fig. 3, the virus titers of samples treated
with AGMA1 did not differ significantly from those determined
for untreated samples (P  0.05), indicating that AGMA1 does
not inactivate HPV particles.
AGMA1 interacts with the cell surface via HSPGs. The poly-
cationic nature of AGMA1 (15, 18) and its demonstrated capacity
to selectively inhibit HSPG-dependent viruses (11) suggested that
AGMA1 could inhibit HPV infection by interacting with cell sur-
face HSPGs. To investigate this hypothesis, we first investigated
the effective capacity of AGMA1 to bind to the cell surface via
HSPGs. In the first set of experiments, we exploited the CHO cell
model. BiotinylatedAGMA1boundCHO-K1 cells (which express
HSPGs) in a dose-dependentmanner, with an ED50 equal to 0.004
g/ml and saturation binding being reached at 0.1 g/ml (data
not shown). The binding of b-AGMA1 to A745 CHO-K1 cells
(mutant cells with defective HSPG synthesis) was significantly re-
duced with respect to wild-type CHO-K1 cells (Fig. 4B). More-
over, the binding of AGMA1 to wild-type CHO-K1 cells could be
reduced to a level comparable to or even lower than those mea-
sured in A745 CHO-K1 cells with a 2 M NaCl wash, a treatment
known to disrupt the binding of cationic molecules to HSPGs
(24), and in the presence of a molar excess of heparin, a structur-
ally relatedHSPGantagonist. Also, cell treatmentwith heparinase,
an enzyme that specifically removes the heparan sulfate chains
from cell surface-associated HSPGs, partially inhibited the cell
surface association of AGMA1 (Fig. 4B).
We wondered whether the HSPG dependence of AGMA1
binding to cell surfaces also applied to cervical adenocarcinoma
epithelial cells. Therefore, we evaluated the binding of b-AGMA1
toHeLa cells. As shown in Fig. 4C, b-AGMA1bound to the surface
of HeLa cells in a dose-dependent manner, with an ED50 equal to
0.04 g/ml and saturation binding being reached at 0.5 g/ml.
Also, as seen for CHO-K1 cells, the binding could be efficiently
inhibited by a 2MNaCl wash and by heparin. At variance was the
finding that heparinase treatment, which removed HSPGs almost
completely from HeLa cell surfaces (Fig. 4E), exerted only partial
inhibition (Fig. 4D). Taken together, these data suggest that the
binding of AGMA1 to the cell surface depends on HSPGs but also
on other (as yet unidentified) receptors.
To confirm further the interaction of AGMA1 with HSPGs,
we evaluated the capacity of AGMA1 to bind to heparin (a
structurally similar molecule) immobilized on a BIAcore sen-
sor chip, a cell-free model that resembles the interactions of
cationic proteins with cell surface HSPGs (28). In a typical
experiment, increasing concentrations of AGMA1 were in-
jected over the heparin surface, and a set of sensograms were
obtained (Fig. 4E). An association rate constant (kon) equal to
5.3  104 M1 s1 and a low dissociation rate constant (koff)
equal to 1.2  103 s1 characterized the interaction of
AGMA1with immobilized heparin. Thus, the AGMA1-heparin
interaction occurred with relatively high affinity (dissociation
constant [Kd] calculated independently of AGMA1 concentra-
tions as koff/kon equal to 22.6 nM). Finally, equilibrium binding
data from Fig. 4E were used to generate the saturation curve
shown in Fig. 4F, which in turn was used to calculate a Kd value
independent of kinetic parameters; a Kd value equal to 17 nM
was obtained, very similar to that calculated above.
AGMA1 blocks HPV binding to host cells through direct in-
teraction with cells. Having demonstrated the interaction be-
tween AGMA1 and the cell surface, we wanted to examine
TABLE 2 AGMA1 antiviral activity against different types of
papillomavirus PsVs
Genotype
IC50 (95% CI)
(g/ml)a CC50 (g/ml) SI
HPV-16 0.53 (0.51–0.55) 300 566
HPV-31 0.36 (0.28–0.46) 300 836
HPV-45 0.74 (0.70–1.80) 300 407
HPV-6 0.54 (0.36–0.81) 300 553
BPV-1 0.34 (0.23–0.50) 300 875
a Values are means and CIs for three separate determinations. IC50, 50% inhibitory
concentration; CI, confidence interval; CC50, 50% cytotoxic concentration; SI,
selectivity index.
FIG 3 AGMA1 does not inactivate HPV PsV particles. HPV PsVs were incubated with 3.6g/ml AGMA1 for 2 h at 4°C or 37°C. Mixtures were then titrated on
HeLa cells at high dilutions, such that the concentration of compound was not active. The titers, expressed in focus-forming units (ffu) per milliliter, are means
and standard errors of the means (SEMs) for triplicates.
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whether AGMA1 exerted its inhibitory activity by blocking HPV
attachment. To this end, preattachment and attachment assays
were performed. As shown in Fig. 5A and B, AGMA1 strongly
inhibited HPV-16 infection under both experimental conditions,
with IC50s of 2.21 g/ml and 1.01 g/ml, respectively. This result
suggested that the antiviral activity depended on the capacity of
AGMA1 to prevent virus binding to the cell surface. To verify this
hypothesis, aWestern blot analysis was carried out to detect theHPV
particlesboundtocells treatedwithAGMA1beforeorduring thePsV
inoculation. In the same assay, heparin was used as a reference com-
pound,beingaknowninhibitorofHPVattachment.As showninFig.
5C, pretreatment with AGMA1 totally prevented the binding of
HPV-16PsV. Incontrast,heparinwasonly slightlyactivewhenadded
before the virus inoculum.When the compoundswere addedduring
infection at 4°C (Fig. 5D), they were both able to inhibit HPV bind-
ing. These results support the hypothesis thatAGMA1preventsHPV
attachment through direct interactions with cells, instead of binding
to the virus particle as heparin does.
To explore further the inhibitory activity of AGMA1 when
added to the cells before infection, we performed a pretreatment
assay in which the virus inoculum was added 23, 5, 3, or 1 h after
the cells were exposed to 100 g/ml or 33 g/ml AGMA1 (two
doses higher than IC90) for 1 h and then washed. As shown in Fig.
6, addition of the virus inoculum 5, 3, or 1 h after AGMA1 pre-
treatment resulted in almost complete suppression of infection
(97%) for all doses of AGMA1; at 23 h posttreatment, 76.7%
inhibition or 45.2% inhibition was observed in cells treated with
100 g/ml or 33 g/ml, respectively.
AGMA1displacesHPV-16bound to cells. Itwas reportedpre-
viously that HPV exhibits slow entry kinetics, with an average
half-time of 12 h for HPV-16 (30). Therefore, we used postattach-
ment assays to investigate whether AGMA1 could displace bound
HPV PsVs. We first performed an entry assay in which the virus
was incubated with cells for 2 h at 4°C, a condition that allows
virus attachment but not entry. Immediately after removal of the
virus inoculum, AGMA1 was added to the cells and the tempera-
ture was shifted to 37°C to allow virus entry. Five hours later, a
time sufficient to allow detectable amounts of PsVs to enter the
cells, the virus particles that had bound but not entered were de-
tached by washing with PBS at pH 10.5 (23) or with medium. The
IC50 determined forAGMA1 in the entry assaywith PBS (pH10.5)
washing was 2.07g/ml, while the value in the assay withmedium
washing was 2.37 g/ml, demonstrating the ability of AGMA1 to
FIG 4 (A to D) Binding of AGMA1 to heparin and HSPGs. (A) Wild-type
CHO-K1 cells and HSPG-deficient A745 CHO-K1 cells were incubated with
b-AGMA1 (0.01 g/ml) and washed with PBS. (B) In parallel experiments,
wild-type CHO-K1 cells were (i) incubated with b-AGMA1 alone or in the
presence of amolar excess (10g/ml) of heparin, (ii) washedwith PBS alone or
PBS containing 2 MNaCl, or (iii) left untreated or pretreated with heparinase
before b-AGMA1 incubation. (C and D) HeLa cells were incubated with in-
creasing concentrations of b-AGMA1 (C) or were incubated with 0.1 g/ml
b-AGMA1 and subjected to the three different treatments described for
CHO-K1 cells (D). The amounts of cell-associated b-AGMA1 were then mea-
sured. O.D., optical density. Horizontal lines, absorbance values measured for
the negative controls (cells not incubated with b-AGMA1). (E) Immunofluo-
rescence analysis showing HSPG expression on the surface of HeLa cells and
the efficiency of heparinase II treatment. (F) Overlay of blank-subtracted sen-
sorgrams generated by the injection ofAGMA1onto sensor-chip-immobilized
heparin. (G) Saturation curves of the binding of AGMA1 to sensor-chip-im-
mobilized heparin. The saturation curves were obtained using the bound RU
values at equilibrium, calculated from the sensorgrams presented in panel E.
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displace PsV particles already bound to cells. In contrast, when
AGMA1was added after thewashoutwith PBS (pH10.5) (posten-
try assay), no reduction of reporter gene expression could be ob-
served (Fig. 7A). Moreover, we tested the inhibitory activity of
AGMA1when it was added to the cells 2 or 4 h after removal of the
PsV inoculum (Fig. 7B), and we observed that 60% inhibitory
activity was still present 4 h postinfection at the highest dose tested
(i.e., 100 g/ml).
FIG 5 AGMA1 inhibition of HPV binding. (A) In the pretreatment assay, AGMA1 was added to cells for 2 h at 4°C and then washed out, and HPV-16 PsVs
were added. SEAP activity was evaluated 72 h later. (B) In the attachment assay, AGMA1 and HPV-16 PsVs were coincubated on cells for 2 h at 4°C,
followed by washout and 72 h of incubation. The results show means and SEMs for triplicates. (C) Western blotting directed against L1 was performed
after a 2-h pretreatment with AGMA1 and heparin (100 g/ml), followed by washout, addition of HPV-16 PsVs for 4 h at 4°C, and subsequent lysis. (D)
Western blotting directed against L1 was performed after incubation on cells of AGMA1 and heparin (100 g/ml) with HPV-16 PsVs for 4 h at 4°C, with
subsequent lysis.
FIG 6 Prevention of HPV infection by AGMA1 for extended periods following its removal. Cells were pretreated with AGMA1 for 1 h at 37°C at fixed doses of
100 g/ml or 33 g/ml, followed by washout; at different time points postwashout (23, 5, 3, or 1 h), cells were infected with HPV-16 PsVs. After 72 h of
incubation, infection was evaluated. The results show means and SEMs for triplicates. hbi, hours before infection.
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DISCUSSION
The wide distribution of HSPGs on eukaryotic cells and their
strong interactive capacity has made them attractive adhesion
molecules for viruses, such as HPV, herpes simplex virus (HSV),
and HIV (10, 12, 31, 32). On the molecular level, cationic viral
proteins, determinants of infectivity, interact with the negatively
charged sulfate groups present on the GAG chains of HSPGs (8).
In the case of HPV, the basic domains on the L1 and L2 capsid
proteins mediate the initial interaction between the virus and the
HSPGs (33, 34). Therefore, this interaction has been put forward
as being a suitable molecular target for virus attachment inhibi-
tors, with the goal of developing novel topicalmicrobicides for the
prevention of sexually transmitted HPV infections. The present
study shows the prevailingly cationic polymer AGMA1 to be a
broad-spectrum inhibitor of HPV attachment, and it demon-
strates that its inhibitory activity depends, at least in part, on its
capacity to bind to cellular HSPGs. The latter feature is supported
by biochemical, genetic, pharmacological, and enzymatic evi-
dence presented herein. We observed that the binding of AGMA1
to HSPG-deficient A745 CHO-K1 cells was reduced with respect
to wild-type CHO-K1 cells. Moreover, washing with 2 M NaCl,
which is known to disrupt the electrostatic bonds between various
proteins and heparin/HSPGs (24), displaced AGMA1 from the
cell surface. Finally, heparin, a structural analog of HSPG GAG
chains, competed with cell surface HSPGs for AGMA1 binding.
Although both of these treatments have been demonstrated to act
mainly on HSPG binding events (24, 35), the possibility that they
also affect interactions of AGMA1 with other (as yet undefined)
receptors cannot be ruled out. The treatment of cells with hepari-
nase, which specifically and efficiently removes GAG chains from
HSPGs (Fig. 4E), did not completely abolish the binding of
AGMA1 to the cells (leaving 50% of binding unaffected), suggest-
ing that other surface receptors, as yet unidentified,may be able to
interact with the polymer. Of note, beside HSPGs, other cell re-
ceptors have been identified that contribute to HPV infection,
including 64 integrin (36) and annexin A2 (37), and some re-
ports even suggest the possibility that HPV infection occurs in a
HSPG-independent manner (38, 39). Interestingly, the levels of
cell surface expression of HSPGs (40) and of heparinase (41) can
vary during inflammation, which is normally triggered by viral
infections, suggesting the possibility that, depending on the path-
ological setting, HSPGs or other (as yet unidentified) HPV recep-
tors may contribute differently to HPV infection.
Whatever receptors are bound, the interaction of AGMA1with
the cell surface is supported by the observation that AGMA1 pre-
vents virus binding even when AGMA1 is administered before the
virus inoculum (pretreatment assays). In contrast, heparin, a
known attachment inhibitor that interacts directly with the virus
particles rather than with the cells, completely prevents virus
binding only in the presence of the virus (Fig. 5). The modest
activity of heparin observed in Fig. 5C may be explained by inter-
action with an unidentified receptor on the cell surface. Annexin
A2, which has been reported to interact with heparin (42) and to
be involved in HPV-16 entry (37), could be a candidate. Interest-
ingly, AGMA1 suppresses infection even when it is added to cell
cultures after virus attachment has already occurred (Fig. 7), in-
dicating that AGMA1 may be able to displace HPV particles that
are bound to cells but not yet internalized (due to their slow entry
kinetics). Taken together, these results identify valuable proper-
ties of AGMA1 as a topical microbicide that could potentially
preventHPV infections if applied before or immediately after sex-
ual intercourse.
Joyce and coworkers reported that virus-like particles com-
posed of HPV L1 protein bound to heparin with an affinity that
was comparable to those of other heparin-binding proteins (33).
Interestingly, the SPR binding assays performed here also showed
FIG7 AGMA1detachment ofHPV from the cell surface. In the entry assay,HPV-16–GFPPsVswere added to cells for 2 h at 4°C andunboundPsVswerewashed
out. AGMA1 was then added, and the cells were incubated for 5 h at 37°C to allow virus entry. The cells were washed with medium (entry A) or with PBS (pH
10.5) (entry B) to remove viruses that remained outside the cell; 72 h after virus inoculation, GFP expression was evaluated. (A) In the postentry assay, AGMA1
was added not before but after the 5-h incubation at 37°C and the washout with PBS (pH 10.5). (B) In the posttreatment assay, AGMA1 was added 0, 2, or 4 h
after removal of the PsV inoculum; GFP expression was evaluated 72 h later. hpi, hours postinfection. The results show means and SEMs for triplicates.
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that AGMA1 bound to heparin with an affinity (Kd of 17.0 to 22.6
nM) comparable to those of many other heparin-binding viral
proteins (10). Taken together, these data suggest that the binding
of AGMA1 to HSPGs in vivo might occur with an affinity that is
comparable to that ofHPV itself, resulting in efficient competition
between AGMA1 and the virus for cell interactions. This would
result in equally efficient inhibition ofHPV infection, as shown by
the very low IC50 calculated for the inhibitory activity of AGMA1
(0.34 to 0.74 g/ml) (Table 2). Besides affinity, another interest-
ing binding feature displayed by the AGMA1-heparin interaction
is its low dissociation rate constant (koff), which identifies the for-
mation of very stable complexes between the polymer and hepa-
rin. A similar low koff has been calculated for the HPV-heparin
interaction (33). These similarities may be tentatively explained
by the multimeric nature shared by the polymer and HPV, with
both exposing multiple binding domains on their surfaces for the
HSPG GAG chains (themselves presenting multiple binding sites
for their ligands). This kind of situation very often leads to the
establishment of cooperative interactions. Briefly, cooperativity is
a form of allostery in which a macromolecule (AGMA1 or HPV)
has more than one binding site and interaction with a receptor
(HSPGs) at one site increases the affinity at the contiguous site,
stabilizing the complex (10). In vivo, the formation of stable com-
plexes betweenAGMA1 andHSPGsmay result in extended inhib-
itory activity; i.e., once the polymer is bound to HSPGs, it may be
able to keep them masked and prevent virus interactions for pro-
longed periods. Those considerations correlate well with the ob-
servation that, once bound to the cell surface, AGMA1 retains its
inhibitory activity when cells are challenged with HPV 3, 5, and
even 23 h after initial exposure to the polymer (Fig. 6).
The results reported here also point to the possibility that, be-
side HSPGs, AGMA1 binds other (as yet unidentified) receptors
on the cell surface. It is tentatively hypothesized that these recep-
tors bound (and masked) by AGMA1 may be involved in HPV
infection as well, pointing to the compound as a multitarget in-
hibitor that is able to interfere with multiple HPV interactions at
the cell surface, which explains its high efficiency in inhibiting
HPV infections under different experimental conditions.
Additional properties of AGMA1make it appealing for further
development as an active pharmaceutical ingredient of topicalmi-
crobicides. AGMA1 is water soluble, biodegradable, and biocom-
patible. Its preparation process is simple, easily scalable, and en-
vironmentally friendly, taking place in water or alcohols, at room
temperature, and without the need for added catalysts (43). Its
activity is not papillomavirus type restricted, since it extends
across three HPV species belonging to the Alphapapillomavirus
genus of the Papillomaviridae family. Indeed, AGMA1 has been
found to be active against three high-risk oncogenic types,
namely, HPV-16, HPV-31 (species 9), and HPV-45 (species 7),
and one low-risk type (HPV-6, belonging to species 10). Of note,
HPV-31 andHPV-45, whose worldwide prevalence rates in cervi-
cal cancer are about 3% and 7%, respectively (44), are not in-
cluded in the bivalent or quadrivalent vaccines. Interestingly, the
fact that AGMA1 is active against HPV-31, whose attachment
does not appear to be dependent on HSPG (39), suggests that an
additional, as yet unidentified, mechanism of anti-HPV activity
exists. The finding that AGMA1 is active even against BPV-1,
which is phylogenetically distant from Alphapapillomavirus spe-
cies (45), supports the broad-spectrum activity of AGMA1. Since
the existing prophylactic vaccines are HPV type restricted, a
broad-spectrum microbicide could be a useful addition to vacci-
nation programs, especially in resource-limited settings where the
burdens of HPV infections are greatest.
Moreover, AGMA1 was recently reported to inhibit HSV-1
and HSV-2 infectivity (11). This finding supports its use under
conditions in which concomitant infections with various sexually
transmitted viruses may occur, such as in the case of HSV-2 infec-
tion, which enhances the transmission of HIV-1 (46). In turn,
HIV infection-driven immunodeficiency causes well-docu-
mented increases in HPV and HSV infections (47, 48). Of note,
HIV is a HSPG-dependent virus (9) and therefore may also be
sensitive to AGMA1.
In conclusion, our results identify AGMA1 as a lead compound
for further development as an active pharmaceutical ingredient of
a topical microbicide against HPV and other sexually transmitted
viral infections. Several issues remain to be investigated, including
the ability of AGMA1 to interact with the basal cells of wounded
squamous stratified epithelia, which are the targets of HPV infec-
tion. Preclinical efficacy and toxicology studies are ongoing, to
assess the clinical potential of this inhibitor.
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